Analysis of Poop to Discover Cancer Treatments

Persephone Biosciences is at the forefront of synthetic biology, focusing on the intricate relationship between human ecosystems and health. Their research emphasizes the importance of the gut microbiome and its impact on various health outcomes, including disease progression, therapeutic response, nutrition, and longevity. The company has initiated several clinical studies, such as the AMBROSIA study, which aims to explore how diet and lifestyle choices influence the gut microbiome. This study represents a significant step towards utilizing the microbiome and dietary factors as potential therapeutic tools.

In addition to AMBROSIA, Persephone is conducting the My Baby Biome™ study, which investigates the microbiome's role from birth, and the ARGONAUT study, the largest US initiative mapping gut and immune health in cancer patients. These projects aim to identify biomarkers that could lead to new therapeutic developments for cancer treatment and prevention. Furthermore, the Poop for the Cure® initiative focuses on large-scale, data-driven research while ensuring diversity in its participant population, highlighting the company's commitment to understanding health through a comprehensive and inclusive lens.

United States

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Persephone Biosciences

Company Details